investigated the potential of the histamine H1 blocker hydroxyzine to improve sleep in patients with cirrhosis and minimal hepatic encephalopathy. All 35 patients (mean age 56 years [range 36–69 ...
This model paradigm was used to evaluate the most recently available H 1-receptor antagonist, desloratadine, and explains its efficacy in the treatment of allergic diseases.
For the antihistamine desloratadine, in vitro studies have revealed it to be a highly potent H 1-receptor antagonist and inhibitor of inflammatory mediators. Animal models with desloratadine have ...